Mackie Research Capital analyst Andre Uddin downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter